Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/piramal-enterprises-ltd" target="_blank" data-smartkarma-citation="entities:14158:1" rel="noopener">Piramal Enterprises (PIEL IN)</a> obtained shareholders nod for demerging its pharma business and consolidated under Piramal Pharma Limited (PPL). Later, PPL will be listed on India stock exchange.</li>
<li>PPL has a differentiated pharmaceutical business model, with three business verticals. CDMO, the largest revenue contributor, has track record of consistent above-market growth due to its niche and complex capabilities.  </li>
<li>Listed as a separate entity, PPL will see multiple expansion and command premium valuation over other Indian generic drug makers, due to its niche and limited competition portfolio.</li>
</ul>



Piramal Enterprises (PIEL IN) obtained shareholders nod for demerging its pharma business and consolidated under Piramal Pharma Limited (PPL). Later, PPL will be listed on India stock exchange.
PPL has a differentiated pharmaceutical business model, with three business verticals. CDMO, the largest revenue contributor, has track record of consistent above-market growth due to its niche and complex capabilities.  
Listed as a separate entity, PPL will see multiple expansion and command premium valuation over other Indian generic drug makers, due to its niche and limited competition portfolio.


Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business

Forensic Analyst, Trudence Capital Advisors

Nitin Mangal

Forensic Analyst

Trudence Capital Advisors

Trudence Capital Advisors Private Limited is a SEBI-registered Research Analyst, holding SEBI registration number INH000015747. Our firm is dedicated to providing independent and unbiased research on Indian mid to large-cap companies. Trudence Capital is known for its counter-consensus views, with a focus on forensic research and on-ground primary investigations. Our research approach is thorough, involving detailed analysis of accounting practices and governance, alongside extensive channel checks.

Independent & Unbiased Research

Forensic Accounting

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ajanta-pharma-ltd" target="_blank" data-smartkarma-citation="entities:10053:1" rel="noopener">Ajanta Pharma (AJP IN)</a>  together with its subsidiaries, develops, manufactures, and markets finished dosages and markets it both domestic and internationally.</li>
<li>Although the company has been profitable, it does exhibit several concerns on the balance sheet side and few on the governance end.</li>
<li>Major setbacks include elongated cash conversion cycle, declining returns and efficiency ratios, doubts on effectiveness of R&amp;D, and capital allocation woes.</li>
</ul>



Ajanta Pharma (AJP IN)  together with its subsidiaries, develops, manufactures, and markets finished dosages and markets it both domestic and internationally.
Although the company has been profitable, it does exhibit several concerns on the balance sheet side and few on the governance end.
Major setbacks include elongated cash conversion cycle, declining returns and efficiency ratios, doubts on effectiveness of R&amp;D, and capital allocation woes.


<ul>
<li>
<a href="https://www.smartkarma.com/entities/aurobindo-pharma-ltd" target="_blank" data-smartkarma-citation="entities:19974:1" rel="noopener">Aurobindo Pharma (ARBP IN)</a> shares have corrected more than 40% from peak and are trading at discount to peers. The company’s U.S. business is under pressure, resulting in deteriorating profitability.</li>
<li>We are not seeing any immediate respite in the U.S. formulation business. Hence, investors can avoid Aurobindo Pharma shares.  </li>
<li>However, value unlocking through stake sale in injectable business can be a near-term catalyst, resulting in relief rally in the stock.</li>
</ul>



Aurobindo Pharma (ARBP IN) shares have corrected more than 40% from peak and are trading at discount to peers. The company’s U.S. business is under pressure, resulting in deteriorating profitability.
We are not seeing any immediate respite in the U.S. formulation business. Hence, investors can avoid Aurobindo Pharma shares.  
However, value unlocking through stake sale in injectable business can be a near-term catalyst, resulting in relief rally in the stock.


Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

External broker reports(aggregated public sources)

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Ajanta Pharma is a focused player in branded, which constitutes ~70% of the overall sales which are spread across geographies including India</li><li>As of FY21, overall exports: domestic formulations ratio was at 70:30</li><li>Target Price and Valuation: Valued at | 2605 i.e. 26x P/E on FY24E EPS of Rs 100.1</li></ul><div class="content-highlight"><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p></div>

Ajanta Pharma is a focused player in branded, which constitutes ~70% of the overall sales which are spread across geographies including IndiaAs of FY21, overall exports: domestic formulations ratio was at 70:30Target Price and Valuation: Valued at | 2605 i.e. 26x P/E on FY24E EPS of Rs 100.1Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Ajanta Pharmaceuticals: Momentum in Branded Business Buoys Numbers

<p>About the stock: Ajanta Pharma is a focused player in branded, which constitutes ~70% of overall sales, which are spread across geographies, including India.</p><ul><li>As of FY21, overall exports: domestic formulations ratio was at 70:30</li><li>Among exports, Asia accounts for ~35% of export formulations, Africa 33% &amp; US 32%. The company also participates in anti-malarial tenders in Africa (included in Africa)</li></ul><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

About the stock: Ajanta Pharma is a focused player in branded, which constitutes ~70% of overall sales, which are spread across geographies, including India.As of FY21, overall exports: domestic formulations ratio was at 70:30Among exports, Asia accounts for ~35% of export formulations, Africa 33% &amp; US 32%. The company also participates in anti-malarial tenders in Africa (included in Africa)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Ajanta Pharmaceuticals: Strong Performance on All Fronts

India

Ajanta Pharma Limited is a pharmaceutical company involved in the areas of product research, manufacturing, and marketing. The Company's manufacturing capabilities include segments such as antiretrovirals, antimalarials, cardiovascular, dermatology, and ophthalmology. The Company also markets over the counter products that include some nature-based remedies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ajanta Pharma (AJP IN)

Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business

Shareholders’ nod for the proposed demerger will create pharmaceutical-focused listed entity, which should pave the way for value unlocking due to...

Tina Banerjee

Ajanta Pharma: Forensic Analysis

Ajanta Pharms's major setbacks include elongated cash conversion cycle, declining returns and efficiency ratios, doubts on effectiveness of R&D,...

Nitin Mangal

Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business

Aurobindo’s U.S. formulation business is witnessing price erosion, which is impacting the revenue and margin. However, value unlocking in...

Tina Banerjee

Ajanta Pharmaceuticals: Momentum in Branded Business Buoys Numbers

Ajanta Pharma is a focused player in branded, which constitutes ~70% of the overall sales which are spread across geographies including India

ICICI Securities Limited

Ajanta Pharmaceuticals: Strong Performance on All Fronts

Ajanta Pharma is a focused player in branded, which constitutes ~70% of overall sales, which are spread across geographies, including India.

ICICI Securities Limited

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)